EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

JAK-STAT pathway heterogeneity governs immunotherapy response in breast cancer

Jianbo Zhou iD, Heng Zhang, Hailin Tang, Lei Yu, Fu Peng iD

eLife · 2026

DOI: 10.7554/elife.110635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Jianbo Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: West China School of Pharmacy, Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecu…. Hauptthemen laut MEDLINE: Immunotherapy, Signal Transduction, Breast Neoplasms, Janus Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Sichuan Province, Project of State Administration of Traditional Chinese Medicine of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The JAK-STAT pathway (JSP) is a well-known oncogenic cascade; however, recent clinical trials have detected JSP upregulation in breast cancer following anti-PD-1 immunotherapy. This paradoxical observation warrants further investigation into JSP’s intercellular heterogeneity, tumor dynamics, molecular mechanisms, and clinical implications for immunotherapy. JSP expression showed dynamic shifts during breast cancer progression, with higher levels in T cells and paracancerous epithelial cells. In human breast cancer tumor cells, elevated JSP is highly correlated with malignant phenotypes. JSP-high tumor cells overexpressed oncogenic pathways, while exhibiting increased immunosuppressive signaling via the MIF-CD74 signaling axis. In T cells, higher JSP levels were associated with enhanced cytotoxic activity, improved differentiation, and reduced exhaustion, reflecting robust anti-tumor immunity. Analysis of immunotherapy datasets revealed that higher JSP levels were associated with improved responses toward PD-1 inhibitors, particularly in triple-negative breast cancer (TNBC) patients, with JSP serving as a predictive biomarker for immunotherapy sensitivity. As a key JSP component, STAT4 exerts dual roles in breast cancer: it drives tumorigenesis in malignant cells, sustains breast epithelial cell proliferation, and bolsters T-cell anti-tumor functionality, while also acting as a highly accurate biomarker for predicting immunotherapy response. This indicates that JSP targeting demands a nuanced approach: broad inhibition may impair anti-tumor immunity, and optimized therapeutic strategies paired with precise biomarkers are critical to maximize JSP’s utility in breast cancer immunotherapy. Our findings highlight JSP’s functional heterogeneity in epithelial, tumor, and T cells, with high JSP activity correlating with enhanced immunotherapy efficacy in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapySignal TransductionBreast NeoplasmsJanus KinasesSTAT Transcription FactorsHumansFemaleCell Line, TumorT-Lymphocytes

Stichwörter der Autor:innen

JAK-STAT pathwaybreast cancercancer biologyhumanimmunotherapy

Substanzen

Janus KinasesSTAT Transcription Factors

Autor:innen und Institutionen

  • West China School of Pharmacy, Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.

ORCID-Profile: Jianbo Zhou, Fu Peng

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Department of Sichuan Province
  • Project of State Administration of Traditional Chinese Medicine of China
  • Project of Sichuan Provincial Administration of Traditional Chinese Medicine
  • Open Research Fund of State Key Laboratory of Southwestern Chinese Medicine Resources
  • Sichuan University Interdisciplinary Innovation Fund
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Zhou, J., Zhang, H., Tang, H., Yu, L., & Peng, F. (2026). JAK-STAT pathway heterogeneity governs immunotherapy response in breast cancer. eLife. https://doi.org/10.7554/elife.110635

Vancouver

Zhou J, Zhang H, Tang H, Yu L, Peng F. JAK-STAT pathway heterogeneity governs immunotherapy response in breast cancer. eLife. 2026. doi:10.7554/elife.110635

BibTeX
@article{Zhou2026,
  author = {Zhou, Jianbo and Zhang, Heng and Tang, Hailin and Yu, Lei and Peng, Fu},
  title = {JAK-STAT pathway heterogeneity governs immunotherapy response in breast cancer},
  journal = {eLife},
  year = {2026},
  doi = {10.7554/elife.110635}
}
Kostenlos starten →